Tagraxofusp: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) recommended or restricted tagraxofusp, while CIPM (Spain), NYE METODER (Norway) and PBAC (Australia) did not recommend it.
The record spans 3.9 years, opening at AWMSG (Wales) on 2 Feb 2021 and running to 29 Jan 2025.
No assessment is on file from HAS (France), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for tagraxofusp, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 7 records date from 2023 or later.
Against its own class, tagraxofusp is an outlier: 20% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
3 distinct indication wordings are recorded for tagraxofusp by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tagraxofusp, on 2 Feb 2021; CIPM (Spain) did not open a file until 17 Jul 2024 — a wide spread of 3.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2021 alone.
CIPM (Spain) is the only agency to have returned to tagraxofusp, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for tagraxofusp.
The full ledger for tagraxofusp reads 4 not recommended, 1 terminated, 1 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 29 Jan 2025 | Indicación terapéutica autorizada: Elzonris está indicado como monoterapia para el tratamiento de primera línea de pacie… | not financed by the SNS · art. 92 c, d | source |
| PBAC (Australia) | 2023 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Not Recommended | source |
| NICE (England) | 30 Mar 2022 | NICE TA782 | terminated appraisal | source |
| G-BA (Germany) | 2 Dec 2021 | Elzonris — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| NYE METODER (Norway) | 20 Jun 2021 | Behandling av blastisk plasmacytoid dendrittisk celleneoplasi (BPDCN) | not introduced | source |
2 further decisions for tagraxofusp, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 7 decisions for tagraxofusp from 6 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.